ATE457316T1 - Polypeptide zur diagnose und therapie von leishmaniasen - Google Patents

Polypeptide zur diagnose und therapie von leishmaniasen

Info

Publication number
ATE457316T1
ATE457316T1 AT03780614T AT03780614T ATE457316T1 AT E457316 T1 ATE457316 T1 AT E457316T1 AT 03780614 T AT03780614 T AT 03780614T AT 03780614 T AT03780614 T AT 03780614T AT E457316 T1 ATE457316 T1 AT E457316T1
Authority
AT
Austria
Prior art keywords
seq
indian
leishmania
strains
polypeptides
Prior art date
Application number
AT03780614T
Other languages
English (en)
Inventor
Sarman Singh
Ramu Sivakumar
Original Assignee
All India Inst Med
Dept Of Biotechnology India
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by All India Inst Med, Dept Of Biotechnology India filed Critical All India Inst Med
Application granted granted Critical
Publication of ATE457316T1 publication Critical patent/ATE457316T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56905—Protozoa
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2469/00—Immunoassays for the detection of microorganisms
    • G01N2469/20—Detection of antibodies in sample from host which are directed against antigens from microorganisms
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Virology (AREA)
  • Pathology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT03780614T 2003-12-26 2003-12-26 Polypeptide zur diagnose und therapie von leishmaniasen ATE457316T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IN2003/000400 WO2005063803A1 (en) 2003-12-26 2003-12-26 Polypeptides for the diagnosis and therapy of leishmaniasis

Publications (1)

Publication Number Publication Date
ATE457316T1 true ATE457316T1 (de) 2010-02-15

Family

ID=34717534

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03780614T ATE457316T1 (de) 2003-12-26 2003-12-26 Polypeptide zur diagnose und therapie von leishmaniasen

Country Status (9)

Country Link
US (1) US7740859B2 (de)
EP (1) EP1711520B1 (de)
CN (1) CN100480265C (de)
AT (1) ATE457316T1 (de)
AU (1) AU2003288711A1 (de)
BR (1) BR0318688A (de)
DE (1) DE60331266D1 (de)
ES (1) ES2345046T3 (de)
WO (1) WO2005063803A1 (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2303316B1 (de) * 2008-07-25 2013-04-24 Department of Biotechnology Konstruktion einer dna-chimäre zur entwicklung eines impfstoffs gegen leishmaniose und tuberkulose
CN102590508A (zh) * 2012-03-12 2012-07-18 中国疾病预防控制中心寄生虫病预防控制所 检测亲内脏利什曼原虫感染和诊断黑热病的免疫层析试条
WO2016055836A1 (pt) * 2014-10-09 2016-04-14 Universidade Federal De Minas Gerais - Ufmg Processo de produção e uso da proteína rk39-kddr e kit para diagnóstico de leishmaniose
EP4422675A2 (de) * 2021-10-28 2024-09-04 Vida Pharmacal, Inc. Verfahren und antigenzusammensetzung zum schnellen nachweis von chagaskrankheit, leishmaniose und herzwürmern bei menschen und tieren

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5411865A (en) * 1993-01-15 1995-05-02 Iasys Corporation Method of detecting anti-leishmania parasite antibodies
US5912166A (en) 1995-04-21 1999-06-15 Corixa Corporation Compounds and methods for diagnosis of leishmaniasis
US5834592A (en) 1995-09-22 1998-11-10 Corixa Corporation Leishmania antigens for use in the therapy and diagnosis of Leishmaniasis
US6855522B2 (en) 2002-02-27 2005-02-15 Indian Council Of Medical Research Species-specific PCR assay for detection of Leishmania donovani in clinical samples of kala-azar and post kala-azar dermal leishmaniasis

Also Published As

Publication number Publication date
BR0318688A (pt) 2006-12-19
US7740859B2 (en) 2010-06-22
EP1711520A1 (de) 2006-10-18
DE60331266D1 (de) 2010-03-25
WO2005063803A1 (en) 2005-07-14
CN1910197A (zh) 2007-02-07
EP1711520B1 (de) 2010-02-10
ES2345046T3 (es) 2010-09-14
CN100480265C (zh) 2009-04-22
US20080031878A1 (en) 2008-02-07
AU2003288711A1 (en) 2005-07-21

Similar Documents

Publication Publication Date Title
Liu et al. Immunological characterizations of the nucleocapsid protein based SARS vaccine candidates
DE69922261D1 (de) Monoklonale antikörper, antigene sowie diagnose und therapie von bösartigen krankheiten
DE60202877D1 (de) Gezieltes antikörper-verfahren
CN114751965B (zh) 一种新型冠状病毒t细胞抗原表位肽及其在制备疫苗中的应用
HUP0203705A2 (hu) Vegyületek és eljárások Chlamydia-fertőzés kezelésére és diagnózisára
HUP0402048A2 (hu) Eljárás specifikus patogének antigénjeinek azonosítására, izolálására és előállítására
Alimohammadian et al. Assessment of interferon-γ levels and leishmanin skin test results in persons recovered for leishmaniasis
EP1869073B1 (de) Polypeptide von leishmania major und dafür codierende polynukleotide, und deren anwendungen als impfstoffe, therapeutika und diagnostika
Chenik et al. Approaches for the identification of potential excreted/secreted proteins of Leishmania major parasites
CN102108355B (zh) 恶性疟原虫的多表位人工抗原及其用途
CN107091932B (zh) 结核病免疫诊断分子标识及其医药用途
ATE457316T1 (de) Polypeptide zur diagnose und therapie von leishmaniasen
WO2004020609A3 (en) Streptococcus pneumoniae antigens for diagnosis, treatment and prevention of active infection
Iraqi Diagnostic value of semi-purified antigens of hydatid cyst fluid in human cystic echinococcosis
Sing et al. Imported cutaneous diphtheria, Germany, 1997–2003
US10197577B2 (en) Serum antibody assay for determining protection from malaria, and pre-erythrocytic subunit vaccines
Benhnini et al. Comparative evaluation of two vaccine candidates against experimental leishmaniasis due to Leishmania major infection in four inbred mouse strains
WO2010108245A3 (pt) Uso de antígenos de leishmania em método diagnóstico, vacina e terapia para leishmaniose
Hiltke et al. Characterization of a novel lipoprotein expressed by Haemophilus ducreyi
de Pádua Vidigal et al. Enzyme immunoassay using Leishmania (Viannia) braziliensis antigens for laboratorial diagnosis of American cutaneous leishmaniasis
US11034735B2 (en) Hybrid peptide, set of hybrid peptides, composition, uses of the hybrid peptide, method for inducing an immune response and kits
Jaiswal et al. Immunological consequences of stress-related proteins–cytosolic tryparedoxin peroxidase and chaperonin TCP20–identified in splenic amastigotes of Leishmania donovani as Th1 stimulatory, in experimental visceral leishmaniasis
ATE366583T1 (de) Identifizierung von spezifischen differenziell exprimierten antigenen aus mycobacterium und medizinische verwendung der mycobakteriumproteine rv0068 und rv3407
Good Immunological responses from non-exposed donors to malaria antigens: implications for immunity and pathology
ATE256704T1 (de) Antikörper und diagnostizierverfahren zur pestivirusdiagnose

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties